
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon's gross business awards demonstrated an 11% increase on a sequential basis, driven by significant wins from biotech clients and the strengthening of partnerships with large pharmaceutical companies. The company has successfully met or exceeded its financial targets related to the PRA acquisition, positioning itself favorably against funding environment uncertainties while allowing for potential acceleration in clinical trial research. Furthermore, Icon's improving win rate within its client segment underscores its advantageous business mix and enhanced access to key industry players, contributing to a positive long-term outlook.
Bears say
The report indicates that Icon's EBITDA margin expectations for 2025 have been revised downward to the high-19% range, compared to earlier expectations of approximately 20%. This decrease is primarily attributed to unfavorable dynamics affecting gross margins, even though revenue guidance has been raised and EPS margins remain unchanged. Additionally, there are significant downside risks due to factors such as slowed clinical trial activities, uncertainty in biotech funding, and potential impacts from inflation and a slowdown in pharmaceutical R&D spending.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares